Aktienanalyse zu Theriva Biologics Inc (TOVX)TOVXTheriva Biologics Inc

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.16 and an RSI of 29.724, indicating oversold conditions, it may seem tempting to buy. However, the stock has a troubling 1-year change of -43.40% and a forward P/E ratio of 0, suggesting no earnings growth is expected. The main risk is the company's recent financial performance, with a net loss of $2.04 million reported for Q1 2026, which is an improvement but still concerning. Therefore, it is advisable to sell rather than buy at this time.